Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
02:28pm, Monday, 24'th Feb 2025
Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion
3 Biotech/Healthcare Names Under $10 I Am Buying Now
04:21pm, Friday, 21'st Feb 2025
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equ
Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript
02:32pm, Thursday, 20'th Feb 2025
Call End: Ardelyx, Inc. (NASDAQ:ARDX ) Q4 2024 Earnings Conference Call February 20, 2025 8:00 A.M. ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relati
Ardelyx Tops Estimates as Sales Surge
01:58pm, Thursday, 20'th Feb 2025
Ardelyx (ARDX -8.10%), a biopharmaceutical company specializing in innovative treatments for gastrointestinal and kidney diseases, released its fourth-quarter earnings report on Feb. 20. The release h
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
10:36am, Thursday, 20'th Feb 2025
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stre
Ardelyx (ARDX) Meets Q4 Earnings Estimates
09:45am, Thursday, 20'th Feb 2025
Ardelyx (ARDX) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
07:30am, Thursday, 20'th Feb 2025
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
08:01am, Wednesday, 19'th Feb 2025
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy?
11:06am, Thursday, 13'th Feb 2025
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
04:30pm, Thursday, 30'th Jan 2025
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
10:11am, Tuesday, 14'th Jan 2025
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
08:03am, Monday, 13'th Jan 2025
Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited)
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 06'th Jan 2025
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
06:36am, Sunday, 24'th Nov 2024
Ardelyx lost a lawsuit against Medicare, impacting XPHOZAH's revenue potential, with no other major prospects in its pipeline. CMS's decision to move XPHOZAH to the bundled payment system significantl
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
08:00am, Wednesday, 20'th Nov 2024
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
